Measures · D12 in 2022 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Statin Use in Persons with Diabetes (SUPD)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- To lower their risk of developing heart disease, most people with diabetes should take cholesterol medication. This rating is based on the percent of plan members with diabetes who take the most effective cholesterol-lowering drugs. Plans can help make sure their members get these prescriptions filled.
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 40-75 years old who were dispensed at least two diabetes medication fills and received a statin medication fill during the measurement period. The percentage is calculated as the number of member-years of enrolled beneficiaries 40-75 years old who received a statin medication fill during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 40-75 years old with at least two diabetes medication fills during the measurement period (denominator). The SUPD measure is adapted from the measure concept that was developed and endorsed by the Pharmacy Quality Alliance (PQA). See the medication list for this measure. The SUPD measure is calculated using the National Drug Code (NDC) lists updated by the PQA. The complete NDC lists, including diagnosis codes, are posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from Prescription Drug Event (PDE) data submitted by drug plans to the CMS Drug Data Processing Systems (DDPS) and accepted by the 2020 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2020 – December 31, 2020. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore, does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2020 PDE submission deadline are used to calculate this measure. PDE adjustments made post-reconciliation were not reflected in this measure. Additional data sources include the Common Medicare Environment (CME), the Medicare Enrollment Database (EDB), the Common Working File (CWF), the Encounter Data Systems (EDS), and the Risk Adjustment Processing System (RAPS). • CME is used for enrollment information. • EDB is used for hospice enrollment and ESRD status (dialysis start and end dates within the measurement period). • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes. • EDS is used to identify diagnoses based on ICD-10-CM codes. • RAPS is used for diagnosis information, RxHCC - Dialysis Status (most recent available Payment Year).
- Measurement period
- 01/01/2020 – 12/31/2020
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- No
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer enrolled member-years (in the denominator). The following beneficiaries are excluded from the denominator if at any time during the measurement period: • Hospice enrollment • ESRD diagnosis or dialysis coverage dates- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses. Also, the member- years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the episode level, and inclusion in the measure is determined separately for each episode – i.e., to be included for a given episode, the beneficiary must meet the initial inclusion criteria for the measure during that episode. The measure is weighted based on the total number of member years for each episode in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three-month episode, disenrolled for a six-month episode, reenrolled for a three-month episode, and meets the measure criteria during each enrollment episode, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12).
- Disaster policy
- Higher measure star (2021-2022) for contracts with 25% or more enrolled affected by 2020 disasters.
From the 2022 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 83 | 84.5 | +1.5 |
| 3★ | MA-PD | 87 | 89 | +2 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 94 | 95 | +1 |
| 2★ | PDP | 81 | 82.5 | +1.5 |
| 3★ | PDP | 83 | 83.5 | +0.5 |
| 4★ | PDP | 85 | 85.5 | +0.5 |
| 5★ | PDP | 87 | 88 | +1 |
2022 star distribution
Not rated: Plan too new to be measured (154); Not enough data available (51); No data available (39); Plan not required to report measure (10)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 94 % | >= 94 % |
| 2027 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2026 | MA-PD | < 81 % | >= 81 % to < 85 % | >= 85 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2026 | PDP | < 82 % | >= 82 % to < 83 % | >= 83 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2025 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2025 | PDP | < 80 % | >= 80 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2024 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 92 % | >= 92 % |
| 2024 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2023 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 86 % | >= 86 % to < 90 % | >= 90 % |
| 2023 | PDP | < 80 % | >= 80 % to < 82 % | >= 82 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2022 | MA-PD | < 76 % | >= 76 % to < 80 % | >= 80 % to < 84 % | >= 84 % to < 88 % | >= 88 % |
| 2022 | PDP | < 77 % | >= 77 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 84 % | >= 84 % |
| 2021 | MA-PD | < 77 % | >= 77 % to < 81 % | >= 81 % to < 83 % | >= 83 % to < 87 % | >= 87 % |
| 2021 | PDP | < 74 % | >= 74 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 85 % | >= 85 % |
| 2020 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 81% | ? 81% to < 83% | ? 83% |
| 2020 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 79% | ? 79% to < 83% | ? 83% |
| 2019 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 80% | ? 80% to < 83% | ? 83% |
| 2019 | PDP | < 73% | ? 73% to < 77% | ? 77% to < 79% | ? 79% to < 82% | ? 82% |
Lowest-scoring contracts, 2022
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S8182 Amerigroup | Elevance Health, Inc. | — | 75 | 1 | — | 7 | 0% |
| H5140 Blue Cross Blue Shield of Arizona (AZ Blue) | Blue Cross Blue Shield of Arizona | — | 63 | 1 | — | 21 | 0% |
| H8067 Provider Partners Health Plans | Rifkin Managed Care Holding, LLC | 0 | 66 | 1 | 0 | 18 | 0% |
| H2392 Kansas Health Advantage | Kansas Superior Select | 873 | 70 | 1 | 0 | 14 | 0% |
| H6743 ATRIO Health Plans | ATRIO Health Plans | 21,042 | 71 | 1 | 0 | 13 | 1% |
| H5398 Wellcare by Allwell | Centene Corporation | — | 71 | 1 | — | 13 | 1% |
| H5117 Wellcare | Centene Corporation | 0 | 72 | 1 | 0 | 12 | 1% |
| H3206 Presbyterian Insurance Company, Inc. | Presbyterian Healthcare Services | — | 73 | 1 | 0 | 11 | 1% |
| H6379 Clear Spring Health | Group 1001 | — | 73 | 1 | — | 11 | 1% |
| H3810 AllCare Advantage | AllCare Health, Inc. | 2,485 | 73 | 1 | 0 | 11 | 1% |
| H7063 Blue Cross and Blue Shield of Kansas | Blue Cross Blue Shield of Kansas | 10,212 | 73 | 1 | — | 11 | 1% |
| H8293 Clear Spring Health | Group 1001 | — | 73 | 1 | — | 11 | 1% |
| H4754 PacificSource Medicare | PacificSource | 2,527 | 73 | 1 | 0 | 11 | 1% |
| S2668 Farm Bureau Health Plans | Tennessee Rural Health Improvement Association | — | 77 | 2 | 0 | 5 | 2% |
| S6946 Clear Spring Health | Group 1001 | — | 77 | 2 | — | 5 | 2% |
| H1304 Regence BlueShield of Idaho | Cambia Health Solutions, Inc. | 902 | 74 | 1 | 0 | 10 | 2% |
| H6316 Healthy Blue | Elevance Health, Inc. | 3,391 | 74 | 1 | — | 10 | 2% |
| H1350 Blue Cross of Idaho | Gemstone Holdings, Inc. | 32,406 | 74 | 1 | 0 | 10 | 2% |
| H2582 UnitedHealthcare | UnitedHealth Group, Inc. | — | 74 | 1 | — | 10 | 2% |
| R7220 Humana | Humana Inc. | 2,904 | 74 | 1 | 0 | 10 | 2% |
| H6348 Wellcare | Centene Corporation | 5,890 | 75 | 1 | 0 | 9 | 3% |
| H8604 The Health Plan | The Health Plan of West Virginia, Inc. | 7,183 | 75 | 1 | 0 | 9 | 3% |
| H8093 Georgia Health Advantage | Mitchell Family Office | 2,064 | 75 | 1 | — | 9 | 3% |
| H6528 UnitedHealthcare | UnitedHealth Group, Inc. | — | 75 | 1 | 0 | 9 | 3% |
| H3814 ATRIO Health Plans | ATRIO Health Plans | 1,997 | 76 | 2 | +1 | 8 | 4% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D11 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2025 – 12/31/2025 | 1 | Prescription Drug Events |
| 2026 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2024 – 12/31/2024 | 1 | Prescription Drug Events |
| 2025 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2023 – 12/31/2023 | 1 | Prescription Drug Events |
| 2024 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2022 – 12/31/2022 | 1 | Prescription Drug Events |
| 2023 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2021 – 12/31/2021 | 1 | Prescription Drug Events |
| 2022 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2018 – 12/31/2018 | 1 | Prescription Drug Events |
| 2019 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2017 – 12/31/2017 | 1 | Prescription Drug Events |